Emerging roles of Lipasin as a critical lipid regulator

Biochemical and Biophysical Research Communications

Volumn 432, Issue 3, 2013, Pages 401-405

  Zhang, Ren ^a   Abou Samra, Abdul B ^a,b  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HAMAD MEDICAL CORPORATION   (Qatar)

Author keywords

ANGPTL8; C19orf80; Gm6484; Lipasin; RIFL; Triglycerides

Indexed keywords

AGENTS AFFECTING LIPID METABOLISM; ANGIOPOIETIN; ANGIOPOIETIN LIKE PROTEIN 3; ANGIOPOIETIN LIKE PROTEIN 4; ANGIOPOIETIN LIKE PROTEIN 8; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN LIPASE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MESSENGER RNA; UNCLASSIFIED DRUG;

ADENOVIRUS; ADIPOGENESIS; COLD; DIET RESTRICTION; DRUG TARGETING; ENVIRONMENT; FRAMESHIFT MUTATION; GENE; GENE EXPRESSION; HUMAN; LIPASIN GENE; LIPID METABOLISM; METABOLIC SYNDROME X; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN CLEAVAGE; RISK FACTOR; SHORT SURVEY; TRIACYLGLYCEROL BLOOD LEVEL;

ADIPOGENESIS; ANGIOPOIETINS; ANIMALS; CHOLESTEROL, HDL; CHOLESTEROL, LDL; COLD TEMPERATURE; HUMANS; LIPID METABOLISM; LIPOPROTEIN LIPASE; METABOLIC SYNDROME X; MICE; PEPTIDE HORMONES; PROTEIN CONFORMATION; TRIGLYCERIDES;

ADENOVIRIDAE; MUS;

EID: 84874976157     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2013.01.129     Document Type: Short Survey

References (40)

1. Eckel R.H., Grundy S.M., Zimmet P.Z. The metabolic syndrome. Lancet 2005, 365:1415-1428.
2. Popkin B.M., Doak C.M. The obesity epidemic is a worldwide phenomenon. Nutr. Rev. 1998, 56:106-114.
3. Grundy S.M., Cleeman J.I., Daniels S.R., Donato K.A., et al. Diagnosis and management of the metabolic syndrome - an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005, 112:2735-2752.
4. Labreuche J., Touboul P.J., Amarenco P. Plasma triglyceride levels and risk of stroke and carotid atherosclerosis: a systematic review of the epidemiological studies. Atherosclerosis 2009, 203:331-345.
5. Nordestgaard B.G. The vascular endothelial barrier-selective retention of lipoproteins. Curr. Opin. Lipidol. 1996, 7:269-273.
6. Proctor S.D., Vine D.F., Mamo J.C. Arterial retention of apolipoprotein B(48)- and B(100)-containing lipoproteins in atherogenesis. Curr. Opin. Lipidol. 2002, 13:461-470.
7. Kolovou G.D., Anagnostopoulou K.K., Daskalopoulou S.S., Mikhailidis D.P., et al. Clinical relevance of postprandial lipaemia. Curr. Med. Chem. 2005, 12:1931-1945.
8. Zhang R. Lipasin, a novel nutritionally-regulated liver-enriched factor that regulates serum triglyceride levels. Biochem. Biophys. Res. Commun. 2012, 424:786-792.
9. Fu Z., Yao F., Abou-Samra A.B., Zhang R. Lipasin, thermoregulated in brown fat, is a novel but atypical member of the angiopoietin-like protein family. Biochem. Biophys. Res. Commun. 2013, 430:1126-1131.
10. Ren G., Kim J.Y., Smas C.M. Identification of RIFL, a novel adipocyte-enriched insulin target gene with a role in lipid metabolism. Am. J. Physiol. Endocrinol. Metab. 2012, 303:E334-E351.
11. Quagliarini F., Wang Y., Kozlitina J., Grishin N.V., et al. Atypical angiopoietin-like protein that regulates ANGPTL3. Proc. Natl. Acad. Sci. USA 2012, 109:19751-19756.
12. Mattijssen F., Kersten S. Regulation of triglyceride metabolism by angiopoietin-like proteins. Biochim. Biophys. Acta 2012, 1821:782-789.
13. Koishi R., Ando Y., Ono M., Shimamura M., et al. ANGPTL3 regulates lipid metabolism in mice. Nat. Genet. 2002, 30:151-157.
14. Koster A., Chao Y.B., Mosior M., Ford A., et al. Transgenic angiopoietin-like (ANGPTL)4 overexpression and targeted disruption of ANGPTL4 and ANGPTL3: regulation of triglyceride metabolism. Endocrinology 2005, 146:4943-4950.
15. Shimizugawa T., Ono M., Shimamura M., Yoshida K., et al. ANGPTL3 decreases very low density lipoprotein triglyceride clearance by inhibition of lipoprotein lipase. J. Biol. Chem. 2002, 277:33742-33748.
16. Shimamura M., Matsuda M., Yasumo H., Okazaki M., et al. Angiopoietin-like protein3 regulates plasma HDL cholesterol through suppression of endothelial lipase. Arterioscler. Thromb. Vasc. Biol. 2007, 27:366-372.
17. Shimamura M., Matsuda M., Kobayashi S., Ando Y., et al. Angiopoietin-like protein 3, a hepatic secretory factor, activates lipolysis in adipocytes. Biochem. Biophys. Res. Commun. 2003, 301:604-609.
18. Ono M., Shimizugawa T., Shimamura M., Yoshida K., et al. Protein region important for regulation of lipid metabolism in angiopoietin-like 3 (ANGPTL3): ANGPTL3 is cleaved and activated in vivo. J. Biol. Chem. 2003, 278:41804-41809.
19. Camenisch G., Pisabarro M.T., Sherman D., Kowalski J., et al. ANGPTL3 stimulates endothelial cell adhesion and migration via integrin alpha vbeta 3 and induces blood vessel formation in vivo. J. Biol. Chem. 2002, 277:17281-17290.
20. Kim I., Kim H.G., Kim H., Kim H.H., et al. Hepatic expression, synthesis and secretion of a novel fibrinogen/angiopoietin-related protein that prevents endothelial-cell apoptosis. Biochem. J. 2000, 346(Pt 3):603-610.
21. Yoon J.C., Chickering T.W., Rosen E.D., Dussault B., et al. Peroxisome proliferator-activated receptor gamma target gene encoding a novel angiopoietin-related protein associated with adipose differentiation. Mol. Cell. Biol. 2000, 20:5343-5349.
22. Kersten S., Mandard S., Tan N.S., Escher P., et al. Characterization of the fasting-induced adipose factor FIAF, a novel peroxisome proliferator-activated receptor target gene. J. Biol. Chem. 2000, 275:28488-28493.
23. Lei X., Shi F., Basu D., Huq A., et al. Proteolytic processing of angiopoietin-like protein 4 by proprotein convertases modulates its inhibitory effects on lipoprotein lipase activity. J. Biol. Chem. 2011, 286:15747-15756.
24. Chomel C., Cazes A., Faye C., Bignon M., et al. Interaction of the coiled-coil domain with glycosaminoglycans protects angiopoietin-like 4 from proteolysis and regulates its antiangiogenic activity. FASEB J. 2009, 23:940-949.
25. Sukonina V., Lookene A., Olivecrona T., Olivecrona G. Angiopoietin-like protein 4 converts lipoprotein lipase to inactive monomers and modulates lipase activity in adipose tissue. Proc. Natl. Acad. Sci. USA 2006, 103:17450-17455.
26. Lichtenstein L., Mattijssen F., de Wit N.J., Georgiadi A., et al. ANGPTL4 protects against severe proinflammatory effects of saturated fat by inhibiting fatty acid uptake into mesenteric lymph node macrophages. Cell Metab. 2010, 12:580-592.
27. Desai U., Lee E.C., Chung K., Gao C., et al. Lipid-lowering effects of anti-angiopoietin-like 4 antibody recapitulate the lipid phenotype found in angiopoietin-like 4 knockout mice. Proc. Natl. Acad. Sci. USA 2007, 104:11766-11771.
28. Lee E.C., Desai U., Gololobov G., Hong S., et al. Identification of a new functional domain in angiopoietin-like 3 (ANGPTL3) and angiopoietin-like 4 (ANGPTL4) involved in binding and inhibition of lipoprotein lipase (LPL). J. Biol. Chem. 2009, 284:13735-13745.
29. Teslovich T.M., Musunuru K., Smith A.V., Edmondson A.C., et al. Biological, clinical and population relevance of 95 loci for blood lipids. Nature 2010, 466:707-713.
30. Romeo S., Pennacchio L.A., Fu Y., Boerwinkle E., et al. Population-based resequencing of ANGPTL4 uncovers variations that reduce triglycerides and increase HDL. Nat. Genet. 2007, 39:513-516.
31. Talmud P.J., Smart M., Presswood E., Cooper J.A., et al. ANGPTL4 E40K and T266M: effects on plasma triglyceride and HDL levels, postprandial responses, and CHD risk. Arterioscler. Thromb. Vasc. Biol. 2008, 28:2319-2325.
32. Musunuru K., Pirruccello J.P., Do R., Peloso G.M., et al. Exome sequencing, ANGPTL3 mutations, and familial combined hypolipidemia. N. Engl. J. Med. 2010, 363:2220-2227.
33. Romeo S., Yin W., Kozlitina J., Pennacchio L.A., et al. Rare loss-of-function mutations in ANGPTL family members contribute to plasma triglyceride levels in humans. J. Clin. Invest. 2009, 119:70-79.
34. Tang T., Li L., Tang J., Li Y., et al. A mouse knockout library for secreted and transmembrane proteins. Nat. Biotechnol. 2010, 28:749-755.
35. Expert Panel on Detection Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002, 106:3143-3421. Third Report of the National Cholesterol Education Program (NCEP).
36. Baigent C., Keech A., Kearney P.M., Blackwell L., et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005, 366:1267-1278.
37. Preiss-Landl K., Zimmermann R., Hammerle G., Zechner R. Lipoprotein lipase: the regulation of tissue specific expression and its role in lipid and energy metabolism. Curr. Opin. Lipidol. 2002, 13:471-481.
38. Kersten S., Lichtenstein L., Steenbergen E., Mudde K., et al. Caloric restriction and exercise increase plasma ANGPTL4 levels in humans via elevated free fatty acids. Arterioscler. Thromb. Vasc. Biol. 2009, 29:969-974.
39. Xu A., Lam M.C., Chan K.W., Wang Y., et al. Angiopoietin-like protein 4 decreases blood glucose and improves glucose tolerance but induces hyperlipidemia and hepatic steatosis in mice. Proc. Natl. Acad. Sci. USA 2005, 102:6086-6091.
40. Inukai K., Nakashima Y., Watanabe M., Kurihara S., et al. ANGPTL3 is increased in both insulin-deficient and -resistant diabetic states. Biochem. Biophys. Res. Commun. 2004, 317:1075-1079.